Walleye Capital
PRME icon

Walleye Capital’s Prime Medicine PRME Stock Holding History

Walleye Capital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,139
Closed -$160K – 4855
2025
Q4 		$160K Buy
+46,139
New +$205K ﹤0.01% 3651
2025
Q1 		– Sell
-403,739
Closed -$1.18M – 4951
2024
Q4 		$1.18M Buy
403,739
+295,365
+273% +$1.04M ﹤0.01% 2238
2024
Q3 		$419K Buy
+108,374
New +$502K ﹤0.01% 3463
2024
Q2 		– Sell
-10,443
Closed -$73.1K – 5913
2024
Q1 		$73.1K Sell
10,443
-57,863
-85% -$439K ﹤0.01% 4540
2023
Q4 		$605K Buy
68,306
+57,606
+538% +$444K ﹤0.01% 2790
2023
Q3 		$102K Buy
+10,700
New +$139K ﹤0.01% 3932
2023
Q1 		– Sell
-30,000
Closed -$557K – 4280
2022
Q4 		$557K Buy
+30,000
New +$542K 0.01% 1378

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Walleye Capital's PRME Position: Q1 2026 in Review

Walleye Capital sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 46,139 shares — an estimated $160K sold.

Walleye Capital first reported a position in PRME in Q4 2022 and held it in 7 quarters. The position peaked at $1.18M in Q4 2024. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Walleye Capital reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 46,139 Prime Medicine shares in Q1 2026, an estimated $160K.
  • Walleye Capital first reported a position in Prime Medicine in Q4 2022 and held it in 7 quarters.
  • Walleye Capital's Prime Medicine position peaked at $1.18M in Q4 2024.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.